Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000950170-25-075515
Filing Date
2025-05-20
Accepted
2025-05-20 21:00:40
Documents
3

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 14709
2 EX-99.1 ck0000000000-ex99_1.pdf EX-99.1 14232
3 EX-99.2 ck0000000000-ex99_2.pdf EX-99.2 57008
  Complete submission text file 0000950170-25-075515.txt   114937
Mailing Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080
Business Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080 650.515.3185
CytomX Therapeutics, Inc. (Subject) CIK: 0001501989 (see all company filings)

EIN.: 273521219 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-89140 | Film No.: 25970645
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 2740 SAND HILL ROAD 2ND FLOOR MENLO PARK CA 94025
Business Address 2740 SAND HILL ROAD 2ND FLOOR MENLO PARK CA 94025 650-854-5700
Longitude Capital Partners V, LLC (Filed by) CIK: 0002018312 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G